284 related articles for article (PubMed ID: 30528886)
1. Molecular tumor heterogeneity in muscle invasive bladder cancer: Biomarkers, subtypes, and implications for therapy.
da Costa JB; Gibb EA; Nykopp TK; Mannas M; Wyatt AW; Black PC
Urol Oncol; 2022 Jul; 40(7):287-294. PubMed ID: 30528886
[TBL] [Abstract][Full Text] [Related]
2. Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer.
Chedgy EC; Douglas J; Wright JL; Seiler R; van Rhijn BW; Boormans J; Todenhöfer T; Dinney CP; Collins CC; Van der Heijden MS; Black PC
Urol Oncol; 2016 Oct; 34(10):469-76. PubMed ID: 27317490
[TBL] [Abstract][Full Text] [Related]
3. New horizons in bladder cancer research.
Boormans JL; Zwarthoff EC; Black PC; Goebell PJ; Kamat AM; Nawroth R; Seiler R; Williams SB; Schmitz-Dräger BJ
Urol Oncol; 2020 Dec; 38(12):867-885. PubMed ID: 30852032
[TBL] [Abstract][Full Text] [Related]
4. Multilayer spectrum of intratumoral heterogeneity in basal bladder cancer.
Sirab N; Drubay D; Maillé P; Popova T; Ngo C; Gentien D; Moktefi A; Soyeux-Porte P; Pelletier R; Reyes C; Henry E; Pouessel D; Vordos D; Lebret T; de Reyniès A; Paoletti X; Radvanyi F; Allory Y
J Pathol; 2022 Jan; 256(1):108-118. PubMed ID: 34611919
[TBL] [Abstract][Full Text] [Related]
5. Intratumoral Heterogeneity of Molecular Subtypes in Muscle-invasive Bladder Cancer-An Extensive Multiregional Immunohistochemical Analysis.
Schallenberg S; Dragomir MP; Anders P; Ebner B; Volz Y; Eismann L; Rodler S; Casuscelli J; Buchner A; Klauschen F; Stief C; Horst D; Schulz GB
Eur Urol Focus; 2023 Sep; 9(5):788-798. PubMed ID: 37076398
[TBL] [Abstract][Full Text] [Related]
6. The role of biomarkers in bladder preservation management of muscle-invasive bladder cancer.
Mitin T; Choudhury A
World J Urol; 2019 Sep; 37(9):1767-1772. PubMed ID: 30218307
[TBL] [Abstract][Full Text] [Related]
7. Tumor heterogeneity in muscle-invasive bladder cancer.
Kang HW; Kim WJ; Choi W; Yun SJ
Transl Androl Urol; 2020 Dec; 9(6):2866-2880. PubMed ID: 33457261
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers for precision medicine in bladder cancer.
Kojima T; Kawai K; Miyazaki J; Nishiyama H
Int J Clin Oncol; 2017 Apr; 22(2):207-213. PubMed ID: 27896485
[TBL] [Abstract][Full Text] [Related]
9. Lower mutant-allele tumor heterogeneity is a biomarker in FGFR3-mutant bladder cancer for better prognosis.
Han Y; Liu X; Ye H; Tian Y; Ji Z
World J Surg Oncol; 2020 Nov; 18(1):310. PubMed ID: 33243261
[TBL] [Abstract][Full Text] [Related]
10. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
11. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
12. ERBB2 Mutations Characterize a Subgroup of Muscle-invasive Bladder Cancers with Excellent Response to Neoadjuvant Chemotherapy.
Groenendijk FH; de Jong J; Fransen van de Putte EE; Michaut M; Schlicker A; Peters D; Velds A; Nieuwland M; van den Heuvel MM; Kerkhoven RM; Wessels LF; Broeks A; van Rhijn BW; Bernards R; van der Heijden MS
Eur Urol; 2016 Mar; 69(3):384-8. PubMed ID: 25636205
[TBL] [Abstract][Full Text] [Related]
13. Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer.
Efstathiou JA; Mouw KW; Gibb EA; Liu Y; Wu CL; Drumm MR; da Costa JB; du Plessis M; Wang NQ; Davicioni E; Feng FY; Seiler R; Black PC; Shipley WU; Miyamoto DT
Eur Urol; 2019 Jul; 76(1):59-68. PubMed ID: 30712971
[TBL] [Abstract][Full Text] [Related]
14. The molecular limitations of biomarker research in bladder cancer.
Vlachostergios PJ; Faltas BM
World J Urol; 2019 May; 37(5):837-848. PubMed ID: 30171455
[TBL] [Abstract][Full Text] [Related]
15. Bladder Tumor Subtype Commitment Occurs in Carcinoma
Wullweber A; Strick R; Lange F; Sikic D; Taubert H; Wach S; Wullich B; Bertz S; Weyerer V; Stoehr R; Breyer J; Burger M; Hartmann A; Strissel PL; Eckstein M
Cancer Res; 2021 Mar; 81(6):1552-1566. PubMed ID: 33472889
[TBL] [Abstract][Full Text] [Related]
16. Optimizing identification of consensus molecular subtypes in muscle-invasive bladder cancer: a comparison of two sequencing methods and gene sets using FFPE specimens.
Koll FJ; Döring C; Olah C; Szarvas T; Köllermann J; Hoeh B; Chun FK; Reis H; Wild PJ
BMC Cancer; 2023 Jun; 23(1):504. PubMed ID: 37270477
[TBL] [Abstract][Full Text] [Related]
17. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.
Necchi A; Raggi D; Gallina A; Ross JS; Farè E; Giannatempo P; Marandino L; Colecchia M; Lucianò R; Bianchi M; Colombo R; Salonia A; Gandaglia G; Fossati N; Bandini M; Pederzoli F; Capitanio U; Montorsi F; de Jong JJ; Dittamore R; Liu Y; Davicioni E; Boormans JL; Briganti A; Black PC; Gibb EA
Eur Urol; 2020 Jun; 77(6):701-710. PubMed ID: 32165065
[TBL] [Abstract][Full Text] [Related]
18. Defects in DNA Repair Genes Predict Response to Neoadjuvant Cisplatin-based Chemotherapy in Muscle-invasive Bladder Cancer.
Plimack ER; Dunbrack RL; Brennan TA; Andrake MD; Zhou Y; Serebriiskii IG; Slifker M; Alpaugh K; Dulaimi E; Palma N; Hoffman-Censits J; Bilusic M; Wong YN; Kutikov A; Viterbo R; Greenberg RE; Chen DY; Lallas CD; Trabulsi EJ; Yelensky R; McConkey DJ; Miller VA; Golemis EA; Ross EA
Eur Urol; 2015 Dec; 68(6):959-67. PubMed ID: 26238431
[TBL] [Abstract][Full Text] [Related]
19. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
20. Triple-marker immunohistochemical assessment of muscle-invasive bladder cancer: Is there prognostic significance?
Labban M; Najdi J; Mukherji D; Abou-Kheir W; Tabbarah A; El-Hajj A
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1313. PubMed ID: 33538412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]